Trial Profile
Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinal neovascularisation; Retinal oedema
- Focus Therapeutic Use
- 19 Dec 2022 Planned number of patients changed from 500 to 800.
- 19 Dec 2022 Planned number of patients changed from 500 to 800.
- 06 Dec 2022 Planned End Date changed from 1 Jan 2021 to 31 Dec 2024.